Pathological Fracture: An Unusual Presentation in Childhood Chronic Myeloid Leukemia
DOI : 10.33371/ijoc.v13i4.675
Introduction: Chronic Myeloid Leukemia is a hematological malignancy driving from myeloproliferative process. It is typified by the presence of the Philadelphia chromosome manifesting in certain distinct complications, including pathological fracture. Pathological fracture is recognized as an extramedullary disease that occurs as a result of transformation of CML into blast crisis phase.
Case Presentation: Here, we report a case of pediatric male CML. After being failed with imatinib therapy, he turned to nilotinib and was unable to achieve a major molecular response. He presented with high blast count and pain in the left arm. He was diagnosed with pathological fracture and blast crisis phase CML. Taken the young age and displacement of fracture into consideration, he was conservatively treated by a combination of immobilization and a higher dose of targeted therapy, nilotinib. The 2-month evaluation revealed clinical union and reduction of blast cells.
Conclusions: Regarding the minimal displacement and age presentation, pathological fracture in pediatric CML requires non-invasive treatment and optimization of antileukemic therapy.
- Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, et al. Chronic myeloid leukemia. JNCCN J Natl Compr Cancer Netw. 2018;16(9):1108–35.
- Granatowicz A, Piatek CI, Moschiano E, El-Hemaidi I, Armitage JD, Akhtari M. An overview and update of chronic myeloid leukemia for primary care physicians. Korean J Fam Med. 2015;36(5):197–202.
- Sharma SK, Seth T, Mishra P, Mahapatra M. Bone Infarcts in a Case of Chronic Myeloid Leukemia: Chronic Phase. Indian J Hematol Blood Transfus. 2012;28(3):187–8.
- Solav S, Bhandari R, Solav P. Skeletal scintigraphy manifestations of hematologic disorders. Indian J Nucl Med. 2013;27(1):59.
- Schabel SI, Tyminski L, Holland RD, Rittenberg GM. The skeletal manifestations of chronic myelogenous leukemia. Skeletal Radiol. 1980;5(3):145–9.
- Prabhash K, Loknath D, Babu KG, Hasib AG, Biswas S, Bapsy PP. Chronic myeloid leukemia with osteolytic bone involvement . J Assoc Physicians India. 2003;51(JUL):740.
- Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, et al. Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate. N Engl J Med. 2006;354(19):2006–13.
- Terpos E, Apperley J, Milojkovic D. Imatinib and chronic myeloid leukemia: Close to the bone. Leuk Lymphoma. 2013;54(8):1581–2.
- O’Sullivan S, Naot D, Callon K, Porteous F, Horne A, Wattie D, et al. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res. 2007;22(11):1679–89.
- Yu H-H, Lu M-Y, Lin D-T, Lin K-H, Tang J-L, Jou S-T. Pathological fracture as a manifestation of extramedullary blastic crisis in chronic myelogenous leukemia: report of one case. Acta Paediatr Taiwan. 2019;47(3):150–4.
- Ishiyama T, Sugimoto M, Wakabayashi Y, Shiokawa Y, Takaku F. [A case of chronic myelogenous leukemia, whose blastic crisis occurred at the same time of the pathologic fracture of the right femur due to myeloblastoma (author’s transl)]. Rinsho Ketsueki. 1981;22(5):661–7.
- Tsukamoto S, Ota S, Ohwada C, Takeda Y, Takeuchi M, Sakaida E, et al. Extramedullary blast crisis of chronic myelogenous leukemia as an initial presentation. Leuk Res Reports. 2013;2(2):67–9.
- Clements DG, Kalmon EH. Chronic Myelogenous Leukemia: Unusual Bone Changes in an Adult. Radiology. 2014;67(3):399–403.
- Ginsberg V, Friedmann A, Meyer L. Infiltration of Bone with Spontaneous Fracture. Jama Network. 2015. p. 4–7.
- Maloisel F, Favre G, Mahmal L, Zamfir A, Andrès E. Isolated lytic bone lesion as extramedullary disease in chronic myelogenous leukemia: A report of three new cases. Eur J Intern Med. 2005;16(4):288–90.
- Kantarjian HM, Keating MJ, Talpaz M, Walters RS, Smith TL, Cork A, et al. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med. 1987;83(3):445–54.
- Terjanian T, Kantarjian H, Keating M, Talpaz M, McCredie K, Freireich EJ. Clinical and prognostic features of patients with Philadelphia chromosome-positive chronic myelogenous leukemia and extramedullary disease. Cancer. 1987;59(2):297–300.
- Inverardi D, Lazzarino M, Morra E, Bernasconi P, Merante S, Canevari A, et al. Extramedullary disease in Ph’-positive chronic myelogenous leukemia: frequency, clinical features and prognostic significance. Haematologica. 1990;75(2):146–8.
- Farmer S, Horváth-Puhó E, Vestergaard H, Hermann AP, Frederiksen H. Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study. Br J Haematol. 2013;163(5):603–10.
- Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM, et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood. 2008;111(5):2538–47.
- O’Sullivan S, Naot D, Callon KE, Watson M, Gamble GD, Ladefoged M, et al. Imatinib mesylate does not increase bone volume in vivo. Calcif Tissue Int. 2011;88(1):16–22.
- Canavese F, Samba A, Rousset M. Pathological fractures in children: Diagnosis and treatment options. Orthop Traumatol Surg Res. 2016;102(1):S149–59.
- Chua GT, Chow KC, So JCC, Cheuk DKL. Aleukaemic leukaemia presenting with pathological fracture. BMJ Case Rep. 2014;2–5.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.